Interstitial lung diseases (ILDs) are progressive fibrotic lung disorders associated with substantial morbidity and mortality. Gastroesophageal reflux disease (GERD) is increasingly recognized as a common comorbidity in ILD, particularly in idiopathic pulmonary fibrosis (IPF) and connective tissue disease-associated ILD (CTD-ILD), though its clinical significance remains incompletely understood.
Methods:
We reviewed current evidence regarding the epidemiology, pathophysiology, diagnosis, and management of GERD in ILD, including reflux prevalence, mechanisms of lung injury, pharmacologic and surgical therapies, and transplant-related outcomes.
Results:
GERD affects more than 50% of patients with ILD and up to 90% of individuals with IPF on objective reflux testing, frequently without classic symptoms. Experimental and clinical studies suggest that recurrent microaspiration of gastric contents may contribute to fibrotic lung injury through epithelial damage, inflammatory signaling, and fibroblast activation. Genetic studies further support an association between GERD predisposition and increased lifetime risk of IPF. Despite these findings, current evidence has not established GERD as a definitive modifiable risk factor for ILD progression. Antacid therapy has not consistently improved lung function decline, exacerbation rates, or mortality in IPF. In contrast, anti-reflux surgery appears beneficial in lung transplant recipients with GERD and is associated with improved allograft outcomes and survival.
Conclusions:
GERD is strongly associated with ILD, but causality and optimal management strategies remain uncertain. Prospective studies with objective reflux assessment are needed to clarify the role of GERD in ILD progression and guide targeted treatment strategies.
PodolanczukAJThomsonCCRemy-JardinM, et al. Idiopathic pulmonary fibrosis: state of the art for 2023. Eur Respir J. 2023;61(4):2200957. doi:10.1183/13993003.00957-2022
2.
JoyGMArbivOAWongCK, et al. Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. Eur Respir Rev. 2023;32(167):220210. doi:10.1183/16000617.0210-2022
3.
RaghuGRemy-JardinMRicheldiL, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18-e47. doi:10.1164/rccm.202202-0399ST
4.
RothEBruniCPetelytskaL, et al. Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort. Rheumatol Oxf Engl. Published online January 8, 2025:keaf016. doi:10.1093/rheumatology/keaf016
5.
TobinRWPopeCEPellegriniCAEmondMJSilleryJRaghuG.Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158(6):1804-1808. doi:10.1164/ajrccm.158.6.9804105
6.
RaghuGFreudenbergerTDYangS, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27(1):136-142. doi:10.1183/09031936.06.00037005
7.
RäihäIMannerRHietanenEHartialaJSouranderL.Radiographic pulmonary changes of gastro-oesophageal reflux disease in elderly patients. Age Ageing. 1992;21(4):250-255. doi:10.1093/ageing/21.4.250
8.
LeeJSSongJWWoltersPJ, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J. 2012;39(2):352-358. doi:10.1183/09031936.00050911
9.
ChenBCaiHRXueSYouWJLiuBJiangHD.Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways. Respirol Carlton Vic. 2016;21(6):1075-1080. doi:10.1111/resp.12815
10.
LeeJSCollardHRRaghuG, et al. Does chronic microaspiration cause idiopathic pulmonary fibrosis?Am J Med. 2010;123(4):304-311. doi:10.1016/j.amjmed.2009.07.033
11.
GhisaMMarinelliCSavarinoVSavarinoE.Idiopathic pulmonary fibrosis and GERD: links and risks. Ther Clin Risk Manag. 2019;15:1081-1093. doi:10.2147/TCRM.S184291
ReynoldsCJDel GrecoM FAllenRJ, et al. The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study. Eur Respir J. 2023;61(5):2201585. doi:10.1183/13993003.01585-2022
14.
TaoHDongYChenXPengL.Mediators of the association between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis. Eur Respir J. 2023;62(6):2300323. doi:10.1183/13993003.00323-2023
15.
SavarinoEBazzicaMZentilinP, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma. Am J Respir Crit Care Med. Published online December 20, 2012. doi:10.1164/rccm.200808-1359OC
16.
VolkmannERTashkinDPLengMKimGHJGoldinJRothMD.Association of symptoms of gastroesophageal reflux, esophageal dilation, and progression of systemic sclerosis-related interstitial lung disease. Arthritis Care Res. 2023;75(8):1690-1697. doi:10.1002/acr.25070
17.
KatzPODunbarKSchnoll-SussmanFHGreerKBYadlapatiRSpechlerSJ.ACG clinical guideline: guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117(1):27-56. doi:10.14309/ajg.0000000000001538
18.
FassR.Gastroesophageal reflux disease. N Engl J Med. 2022;387(13):1207-1216. doi:10.1056/NEJMcp2114026
19.
StanciuCBennettJR.Effects of posture on gastro-oesophageal reflux. Digestion. 1977;15(2):104-109. doi:10.1159/000197991
20.
HamiltonJWBoisenRJYamamotoDTWagnerJLReichelderferM.Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. Dig Dis Sci. 1988;33(5):518-522. doi:10.1007/BF01798350
21.
KaltenbachTCrockettSGersonLB.Are lifestyle measures effective in patients with gastroesophageal reflux disease?: An evidence-based approach. Arch Intern Med. 2006;166(9):965-971. doi:10.1001/archinte.166.9.965
22.
WilsonLJMaWHirschowitzBI.Association of obesity with hiatal hernia and esophagitis. Am J Gastroenterol. 1999;94(10):2840-2844. doi:10.1111/j.1572-0241.1999.01426.x
23.
MehtaRSNguyenLHMaWStallerKSongMChanAT.Association of diet and lifestyle with the risk of gastroesophageal reflux disease symptoms in US women. JAMA Intern Med. 2021;181(4):552-554. doi:10.1001/jamainternmed.2020.7238
24.
KhorYHBissellBGhazipuraM, et al. Antacid medication and antireflux surgery in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Ann Am Thorac Soc. 2022;19(5):833-844. doi:10.1513/AnnalsATS.202102-172OC
25.
JonesMCahnAChaudhuriN, et al. The effectiveness and risks of treating people with idiopathic pulmonary fibrosis with the addition of lansoprazole (TIPAL): study protocol for a randomised placebo-controlled multicentre clinical trial. BMJ Open. 2025;15(2):e088604. doi:10.1136/bmjopen-2024-088604
26.
AsanoYJinninMKawaguchiY, et al. Diagnostic criteria, severity classification and guidelines of systemic sclerosis. J Dermatol. 2018;45(6):633-691. doi:10.1111/1346-8138.14162
27.
TashkinDPVolkmannERTsengCH, et al. Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of scleroderma lung study II. Chest. 2017;151(4):813-820. doi:10.1016/j.chest.2016.11.052
28.
KreuterMBonellaFBlankN, et al. Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis. Rheumatol Oxf Engl. 2023;62(9):3067-3074. doi:10.1093/rheumatology/kead023
29.
LindenPAGilbertRJYeapBY, et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg. 2006;131(2):438-446. doi:10.1016/j.jtcvs.2005.10.014
30.
CarlsonDAHinchcliffMPandolfinoJE.Advances in the evaluation and management of esophageal disease of systemic sclerosis. Curr Rheumatol Rep. 2015;17(1):475. doi:10.1007/s11926-014-0475-y
31.
GasperWJSweetMPGoldenJA, et al. Lung transplantation in patients with connective tissue disorders and esophageal dysmotility. Dis Esophagus Off J Int Soc Dis Esophagus. 2008;21(7):650-655. doi:10.1111/j.1442-2050.2008.00828.x
32.
YamamotoMKamalANGabbardSClarkeJGyawaliCPLeimanDA.Esophageal function testing patterns in the evaluation and management of lung transplantation: results of a national survey. J Clin Gastroenterol. 2024;58(9):857-864. doi:10.1097/MCG.0000000000001955
33.
LeardLEHolmAMValapourM, et al. Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2021;40(11):1349-1379. doi:10.1016/j.healun.2021.07.005
34.
YangNYParishAPosnerS, et al. Acid exposure time is sensitive for detecting gastroesophageal reflux disease and is associated with long-term survival after lung transplant. Dis Esophagus Off J Int Soc Dis Esophagus. 2023;36(8):doac114. doi:10.1093/dote/doac114
35.
D-OvidioFMuraMRidsdaleR, et al. The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D. Am J Transplant. 2006;6(8):1930-1938. doi:10.1111/j.1600-6143.2006.01357.x
36.
Abbassi-GhadiNKumarSCheungB, et al. Anti-reflux surgery for lung transplant recipients in the presence of impedance-detected duodenogastroesophageal reflux and bronchiolitis obliterans syndrome: a study of efficacy and safety. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2013;32(6):588-595. doi:10.1016/j.healun.2013.02.009
37.
KrahelskiOAliINamgoongC, et al. Interventional anti-reflux management for gastro-oesophageal reflux disease in lung transplant recipients: a systematic review and meta-analysis. Surg Endosc. 2025;39(1):19-38. doi:10.1007/s00464-024-11392-8
38.
Leiva-JuarezMMBenvenutoLCostaJ, et al. Identification of lung transplant recipients with a survival benefit after fundoplication. Ann Thorac Surg. 2022;113(6):1801-1810. doi:10.1016/j.athoracsur.2021.05.098
39.
RaziaDMittalSKFournierS, et al. Antireflux surgery versus medical management of gastro-oesophageal reflux after lung transplantation. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 2023;63(3):ezad063. doi:10.1093/ejcts/ezad063
